Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non- albicans Candida Species: Review of the Caspofungin Database
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Increasing rates of invasive candidiasis caused by non- albicans Candida species have been reported worldwide. Particular concerns have been raised for C. parapsilosis because of reduced in vitro susceptibility to echinocandins. We identified 212 patients with invasive candidiasis due to non- albicans Candida species (≥5 cases per species) in 5 clinical trials of caspofungin monotherapy from the pharmaceutical sponsor's (Merck and Co., Inc.) database: 71 cases were caused by C. parapsilosis , 65 by C. tropicalis , 54 by C. glabrata , 10 by C. krusei , 9 by C. guilliermondii , and 5 by C. lusitaniae . One hundred sixty-seven cases caused by C. albicans were also identified. Efficacy was assessed at the end of caspofungin therapy. Success (favorable overall response) required favorable clinical and microbiological responses. The mean APACHE II scores were 16.5 in the non- albicans group and 15.7 in the C. albicans group. Neutropenia at study entry was more common in the non- albicans group (12%) than in the C. albicans group (5%). The median duration of caspofungin therapy was 14 days in both groups. The success rates were 77% in both groups and at least 70% for each non- albicans species: 74% for C. parapsilosis , 71% for C. tropicalis , 85% for C. glabrata , 70% for C. krusei , 89% for C. guilliermondii , and 100% for C. lusitaniae . The times to negative blood culture were similar for the various species. The overall mortality rates were 26% in the non- albicans group and 29% in the C. albicans group. Drug-related serious adverse events and discontinuations due to caspofungin toxicity were uncommon. Although the sample sizes were limited, caspofungin demonstrated favorable efficacy and safety profiles in the treatment of invasive candidiasis caused by the following non- albicans Candida species: C. parapsilosis , C. tropicalis , C. glabrata , C. krusei , C. guilliermondii , and C. lusitaniae .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 4×
“Reason for study entry Primary therapy 47 (87) 9 (100) 8 (80) 5 (100) 69 (97) 62 (95) 199 (94) 151 (90) Salvage therapy 7 (13) 2 (20) 2 (3) 3 (5) 13 (6) 16 (10)”
BackgroundInfluentialComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citationHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 2×
“Bone/joint space 1 (2) 1 (10) 1 (1) 3 (1) 5 (3) Peritoneal fluid 2 (4) 2 (3) 4 (2) 14 (8) Pleural fluid 1 (2) 1 (1) 1 (2) 3 (1) 1 (1) Other 2 (4) 2 (3) 4 (2) 13 (8)”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598933 · Cited by 214 · cited 8×
“Race Caucasian 41 (76) 7 (78) 7 (70) 2 (40) 45 (63) 40 (62) 141 (67) 116 (69) Black 4 (7) 2 (22) 1 (10) 1 (20) 7 (10) 10 (15) 24 (11) 15 (9) Asian 2 (4) 10 (14) 11 (17) 23 (11) 9 (5) Hispanic 6 (11) 2 (20) 1 (20) 9 (13) 3 (5) 21 (10) 20 (12) Other 1 (2) 1 (20) 1 (1) 3 (1) 7 (4)”
BackgroundResultSelf-citation
Cited by
Wisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M. B., Wenzel, R. P., & Seifert, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.005 · Cited by 293
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Occurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Metadata
- Authors
- Colombo, A. L., Ngai, A. L., Bourque, M., Bradshaw, S. K., Strohmaier, K. M., Taylor, A. F., Lupinacci, R. J., & Kartsonis, N. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-05
- Volume
- 54
- Issue
- 5
- Pages
- 1864-1871
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2139051460
- Cited by
- 41
- References
- 5
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non- albicans Candida Species: Review of the Caspofungin Database. https://app.cochat.ai/papers/10.1128/aac.00911-09
- The paper
- Colombo, A. L., Ngai, A. L., Bourque, M., Bradshaw, S. K., Strohmaier, K. M., Taylor, A. F., Lupinacci, R. J., & Kartsonis, N. A. (2010). Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non- albicans Candida Species: Review of the Caspofungin Database. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00911-09
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.